SLS, IBRX And IOVA Join Merck And Lilly On Blackrock's Q3 Buy List - A Vanguard Unit Adds All Of Them Too
| Stock | BlackRock | Vanguard Capital Management | Morgan Stanley |
| Sellas Life Sciences (SLS) | 1.1 million | 716,542 | 274,846 |
| ImmunityBio (IBRX) | 2 million | 3.1 million | -1.3 million |
| Iovance Biotherapeutics (IOVA) | 946,279 | 192,458 | -501,384 |
| Merck (MRK) | 1 million | 190,287 | -406,720 |
| Eli Lilly (LLY) | 395,753 | 392,341 | 151,251 |
Iovance also divided the Vanguard affiliates. While Vanguard Capital Management added 192,458 shares, Vanguard Portfolio Management cut its stake by 2.11 million shares.
What Cancer Drugs Mean To Merck And Lilly
BlackRock's biggest dollar positions among the five were in Lilly and Merck. At quarter-end, it held $78.6 billion in Lilly and $33.1 billion in Merck, compared with $1.1 billion across the three smaller drugmakers. Iovance was its largest holding among the biotechs at $562 million, followed by ImmunityBio at $341 million and Sellas at $199 million.
For Merck, nearly half of quarterly sales came from one cancer drug franchise. Keytruda and its under-the-skin version, Keytruda Qlex, generated $8.6 billion of Merck's $18.1 billion in revenue.
Last month, Merck and Moderna said that adding a personalized experimental cancer vaccine to Keytruda reduced the risk of recurrence or death by 42% compared with Keytruda alone in patients whose melanoma had been surgically removed. Researchers are still following patients to see whether they live longer.
Meanwhile, Lilly's diabetes and obesity drugs drove most of its quarterly growth, but its breast cancer drug Verzenio generated $1.51 billion in sales. Its blood cancer drug Jaypirca also gained a new use in October, when the FDA approved it for certain adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Catalysts For SLS, IBRX And IOVA
Sellas expects to find out this month whether its experimental treatment Galinpepimut-S (GPS) helps people with acute myeloid leukemia (AML) live longer after a second remission. The company confirmed the timing for its Phase 3 Regal trial last week. The trial reached the 80 deaths required to trigger its final analysis last month.
“If successful, we believe GPS could be a transformative new immunotherapy for AML patients in second complete remission,” Sellas CEO Angelos Stergiou said.
On the other hand, ImmunityBio is trying to bring its bladder cancer drug Anktiva to patients earlier. Recently, the company said that adding Anktiva to BCG, a standard treatment, improved response rates over BCG alone in patients with bladder carcinoma in situ who had never received BCG. ImmunityBio plans to seek expanded FDA approval by year-end.
Iovance already sells Amtagvi, a cell therapy for advanced melanoma. U.S. sales rose about 77% year over year to $102 million in the third quarter. Its expansion plans bring Merck back into the story. In a Phase 3 trial, Iovance is testing Amtagvi alongside Merck's Keytruda as a first treatment for advanced melanoma.
How Do Retail Traders Feel About Cancer Stocks?
On Stocktwits, retail sentiment was 'bullish' on SLS amid 'high' message volume, 'neutral' on IBRX amid 'normal' volume, and 'bearish' on IOVA, MRK and LLY, with 'extremely low' volume for IOVA and 'normal' volume for both MRK and LLY.
So far this year, IBRX is up 204%, followed by IOVA at 184%, SLS at 108%, MRK at 40% and LLY at 34%.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment